Victor E. Tong, Jr.

Mr. Victor E. Tong, Jr. is a Partner at Decheng Capital and has been with the firm since its inception.

At Decheng, Mr. Tong focuses on investments in biotechnology and medical technology companies in China and US. Mr. Tong currently serves on the boards of AccuraGen, EpimAb Biotherapeutics, GenapSys, GeneMDx, Levitas, ReadCoor and SentreHeart. He previously served on the boards of past Decheng companies Cirina (acquired by GRAIL) and GeneWEAVE Biosciences (acquired by Roche). Mr. Tong’s investment portfolio also includes 3SBio (1530.HK), Apexigen, ARMO Biosciences, Cellular Research (acquired by Becton Dickinson), China Biologic Products (NASDAQ: CBPO), Hummingbird Bioscience, Invitae (NASDAQ: NVTA) and SINOMED.

Prior to joining Decheng, Mr. Tong was a Principal at Bay City Capital and was a member of the founding team of Nevro (NYSE: NVRO), a Bay City Capital-originated medical device company. He also played a key role in the firm’s investments in Cadence Pharmaceuticals (acquired by Mallinckrodt), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies) and NextWave Pharmaceuticals (acquired by Pfizer). Prior to joining Bay City, Mr. Tong was an investment banker with Morgan Stanley, where he advised healthcare companies on initial public offerings and specialized in strategic advisory work. Prior to Morgan Stanley, Mr. Tong was an entrepreneur at Hana Biosciences (acquired by Spectrum Pharmaceuticals), where he was responsible for pipeline development, licensing and product launch for cancer products. Mr. Tong began his career participating in The Human Genome Project and its race to sequence the human genome as a research assistant at Incyte in 1999.

Mr. Tong is a graduate of the University of California, Berkeley, where he earned a BA degree in Molecular and Cell Biology and a BS degree in Business Administration from the Haas School of Business.